Lewis 2012.

Methods	A patient report of a paediatric patient with glaucoma receiving methylphenidate treatment for 8 years
Participants	Diagnosis of ADHD: DSM‐IV (subtype: combined) Age: 10 years old IQ: within normal limits Sex: female Country: USA Comorbidity: primary open angle glaucoma. Physical examination within normal limits Comedication: latanoprost 0.005% eye drops twice daily Sociodemographics: not stated
Interventions	Methylphenidate type: extended release Methylphenidate dosage: 18 mg/day titrated to 54 mg/day over 6 months Administration schedule: once daily Duration of treatment: 8 years Treatment compliance: not stated
Outcomes	Non‐serious adverse events No exacerbation of glaucoma: Before methylphenidate treatment: after treatment for glaucoma, the patient's intraocular pressure was brought to a stable range between 16 mmHg and 19 mmHg in both eyes During methylphenidate treatment: ophthalmic examination every 6 months showed intraocular pressure consistently in the 16‐19 mmHg range bilaterally
Notes	Key conclusions of the study authors: this report concluded stimulant medication (methylphenidate) should not be withheld in patients with glaucoma as long as intraocular pressure (IOP) remains well controlled Comments from the study authors: the actual risk associated with adrenergic medications in patients with open angle glaucoma is negligible, and there are no studies proving adverse effects on IOP in normal or open angle eyes Supplemental information regarding IQ received through personal email correspondence with the authors in March 2014 (Lewis 2014 [pers comm])